Risk of bias in industry-funded oseltamivir trials: Comparison of core reports versus full clinical study reports

BMJ Open

Volumn 4, Issue 9, 2014, Pages

  Jefferson, Tom ^a   Jones, Mark A ^b   Doshi, Peter ^c   Del Mar, Chris B ^d   Hama, Rokuro ^e   Thompson, Matthew J ^f,g   Onakpoya, Igho ^g   Heneghan, Carl J ^g  

^a Acute Respiratory Infections Group   (Italy)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^d BOND UNIVERSITY   (Australia)

^e Japan Institute of Pharmacovigilance   (Japan)

^f UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; ANTIVIRUS AGENT;

ARTICLE; CLINICAL STUDY; COMPARATIVE STUDY; DRUG DESIGN; DRUG INDUSTRY; FUNDING; OUTCOME ASSESSMENT; RISK ASSESSMENT; STATISTICAL BIAS; ACCESS TO INFORMATION; CLINICAL TRIAL (TOPIC); HUMAN; PUBLISHING; RISK; STANDARDS; STATISTICS;

ACCESS TO INFORMATION; ANTIVIRAL AGENTS; BIAS (EPIDEMIOLOGY); CLINICAL TRIALS AS TOPIC; DRUG INDUSTRY; HUMANS; OSELTAMIVIR; PUBLISHING; RISK; STATISTICS AS TOPIC;

EID: 84907560908     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-005253     Document Type: Article

References (23)

1. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Structure and Content of Clinical Study Reports: E3 [Internet]. 1995 [cited 8 July 2012]. http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E3/E3-Guideline.pdf
2. Doshi P, Jefferson T. Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reports. BMJ Open 2013;3:e002496.
3. European Medicines Agency. European Medicines Agency policy on access to documents (related to medicinal products for human and veterinary use) POLICY/0043 [Internet]. 2010 [cited 14 May 2012]. http://www.ema.europa.eu/docs/en-GB/document-library/Other/2010/11/WC500099473.pdf
4. F. Hoffmann-La Roche Ltd. Roche Global Policy on Sharing of Clinical Trials Data [Internet]. 2013 [cited 19 Jun 2013]. http://roche-trials.com/dataSharingPolicy.action
5. Nisen P, Rockhold F. Access to patient-level data from GlaxoSmithKline clinical trials. N Engl J Med 2013;369:475-8.
6. Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev2012;(1):CD008965.
7. Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
8. Doshi P, Jones M, Jefferson T. Rethinking credible evidence synthesis. BMJ 2012;344:d7898.
9. Doshi P, Jefferson T, Del Mar C. The imperative to share clinical study reports: recommendations from the Tamiflu rxperience. PLoS Med 2012;9:e1001201.
10. Jefferson T, Jones M, Doshi P, et al. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ2014;348:g2545.
11. Wang K, Shun-Shin M, Gill P, et al. Neuraminidase inhibitors for preventing and treating influenza in children (published trials only). Cochrane Database Syst Rev2012;4:CD002744.
12. Jefferson T, Jones M, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Cochrane Database Syst Rev Online 2010;2:CD001265.
13. Kaiser L, Wat C, Mills T, et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003;163:1667-72.
14. Dutkowski R, Smith JR, Davies BE. Safety and pharmacokinetics of oseltamivir at standard and high dosages. IntJ Antimicrob Agents 2010;35:461-7.
15. Hoffman-La Roche, Ltd. Clinical Study Report-Protocol WP16263. A randomized, double blind, parallel group, placebo controlled study of the effect of oseltamivir on ECG intervals in healthy subjects. Report No. 1003328. 2001.
16. Doshi P. Neuraminidase inhibitors-the story behind the Cochrane review. BMJ2009;339:b5164.
17. Vedula SS, Bero L, Scherer RW, et al. Outcome reporting in industry-sponsored trials of gabapentin for off-label use. N Engl J Med. 2009;361:1963-71.
18. Vedula SS, Li T, Dickersin K. Differences in reporting of analyses in internal company documents versus published trial reports: comparisons in industry-sponsored trials in off-label uses of gabapentin. PLoS Med 2013;10:e1001378.
19. Rodgers MA, Brown JVE, Heirs MK, et al. Reporting of industry funded study outcome data: comparison of confidential and published data on the safety and effectiveness of rhBMP-2 for spinal fusion. BMJ 2013;346:f3981.
20. Eyding D, Lelgemann M, Grouven U, et al. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ 2010;341: c4737.
21. Wieseler B, Wolfram N, McGauran N, et al. Completeness of reporting of patient-relevant clinical trial outcomes: comparison of unpublished clinical study reports with publicly available data. PLoS Med 2013;10:e1001526.
22. Jefferson TO, Demicheli V, Di Pietrantonj C, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Cochrane Database Syst Rev Online 2009;2:CD001265.
23. Matheson NJ, Harnden AR, Perera R, et al. Neuraminidase inhibitors for preventing and treating influenza in children. Cochrane Database Syst Rev Online 2007;(1):CD002744.